SCHEMBL3374978

SCHEMBL3374978

COC(=O)c1cc(-c2cnc(Nc3cc(OC)cc(OC)c3)nc2-n2ccc(C(F)(F)F)n2)cnc1NCCS(C)(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYRO3 Q06418 3/20 0.37
MERTK Q12866 2/20 0.37
AXL P30530 3/20 0.36
SIRT5 Q9NXA8 1/20 0.36
CHEK1 O14757 1/20 0.35
MAPK3 P27361 1/20 0.35
LRRK2 Q5S007 1/20 0.34
PTK2 Q05397 2/20 0.34
CNR2 P34972 2/20 0.34
IDH1 O75874 1/20 0.33
JAK2 O60674 1/20 0.33
CYP3A4 P08684 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ZAP70 P43403 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448222 0.94 AXL (0.36) TYRO3MERTKAXLSIRT5CHEK1
SCHEMBL3449402 0.88 TYRO3 (0.40) TYRO3MERTKAXLMAPK3PTK2
SCHEMBL3449763 0.88 RAF1 (0.38) TYRO3MERTKAXLMAPK3CNR2
SCHEMBL3460190 0.87 TYRO3 (0.37) TYRO3MERTKAXLMAPK3PTK2
SCHEMBL3451183 0.87 CNR2 (0.39) TYRO3MERTKAXLCNR2
SCHEMBL3376690 0.85 TYRO3 (0.40) TYRO3MERTKAXLMAPK3PTK2
SCHEMBL13312615 0.84 SYK (0.37) TYRO3MERTKAXLMAPK3CNR2
SCHEMBL3447552 0.84 RAF1 (0.38) TYRO3MERTKAXLCNR2
SCHEMBL3447579 0.83 TYRO3 (0.39) TYRO3MERTKAXLMAPK3PTK2
SCHEMBL13312583 0.83 SIRT5 (0.39) TYRO3MERTKAXLSIRT5JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD TYRO3 2798/4885MERTK 1743/4885AXL 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.